Advertisement

Significance of Regional Draining Lymph Nodes in the Development of Tumor Immunity: Implications for Cancer Immunotherapy

  • Rongxiu Zheng
  • Jorgen Kjaergaard
  • Walter T. Lee
  • Peter A. Cohen
  • Suyu Shu
Part of the Cancer Treatment and Research book series (CTAR, volume 135)

For the majority of human solid cancer, regional draining lymph nodes (LNs) are the initial target of metastases and the LN status serves as the most important prognostic indicator for clinical outcome of patients. In patients with cutaneous melanoma who develop metastases, tumor most often first presents in the ipsilateral regional nodes and appears preferentially in the first LN on the direct lymphatic drainage pathway from a primary melanoma (1, 2).

Keywords

Cancer Immunotherapy Adoptive Immunotherapy Fusion Hybrid Vaccine Site Systemic Antitumor Immunity 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Cochran AJ, Bhuta S, Paul E, Ribas A (2000) The shifting patterns of metastatic melanoma. Clin Lab Med 4:759–783.Google Scholar
  2. 2.
    Cochran AJ, Roberts AA, Saida T (2003) The place of lymphatic mapping and sentinel node biopsy in oncology. Int J Clin Oncol 8:139–150.PubMedCrossRefGoogle Scholar
  3. 3.
    Morton DL, Wen D-R, Wong JH, Economou JS, Cagle LA, Storm FK, Foshag LJ, Cochran AJ (1992) Technical details of intraoperative lymphatic mapping for early stage melanoma. Arch Surg 127:392–399.PubMedGoogle Scholar
  4. 4.
    Cochran AJ, Morton DL, Stern S, Lana AM, Essner R, Wen DR (2001) Sentinel lymph nodes show profound downregulation of antigen-presenting cells of the paracortex: Implications for tumor biology and treatment. Mod Pathol 14:604–608.PubMedCrossRefGoogle Scholar
  5. 5.
    Lana A-M, Wen D-R, Cochran AJ (2001) The morphology, immunophenotype and distribution of paracortical dendritic leukocytes in lymph nodes regional to cutaneous melanoma. Melanoma Res 11:1–10.CrossRefGoogle Scholar
  6. 6.
    Lee JH, Essner R, Torisu-Itakura H, Wanek L, Wang H-J, Morton DL (2004) Factors predictive of tumor-positive nonsentinel lymph nodes after tumor-positive sentinel lymph node dissection for melanoma. J Clin Oncol 22:3677–3684.PubMedCrossRefGoogle Scholar
  7. 7.
    Dudley ME, Wunderlich JR, Robbins PF, Yang JC, Hwu P, Schwartzentruber DJ, Topalian SL, Sherry R, Restifo NP, Hubicki AM, Robinson MR, Raffeld M, Duray P, Seipp CA, Rogers-Freezer L, Morton KE, Mavroukakis SA, White DE, Rosenberg SA (2002) Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 298:850–854.PubMedCrossRefGoogle Scholar
  8. 8.
    Davies AJS, Carter RL, Leuchars E, Wallis V, Koller PC (1969) The morphology of immune reactions in normal, thymectomized and reconstituted mice I. The response to sheep erythrocytes. Immunol 16:57–69.Google Scholar
  9. 9.
    Landsteiner K, Chase MW (1939) Studies on the sensitization of animals with simple chemical compounds. VI. Experiments on the sensitization of guinea pig to poison ivy. J. Exp. Med. 69:767–784.CrossRefGoogle Scholar
  10. 10.
    Sell S, Weigle WO (1959) The relationship between delayed hypersensitivity and circulating antibody induced by protein antigens in guinea pigs. J Immunol 83:257–263.PubMedGoogle Scholar
  11. 11.
    Turk JL, Stone SH (1963) Implications of the cellular changes in lymph nodes during the development and inhibition of delayed type hypersensitivity. In: Amos B, Koprowski H (eds) “Cell-bound Antibodies”. Wistar Institute Press, pp 51.Google Scholar
  12. 12.
    Frey JR, Wenk P (1957) Experimental studies on the pathogenesis of contact eczema in the guinea pig. Int Arch Allergy 11:81–100.PubMedCrossRefGoogle Scholar
  13. 13.
    Hanna MG Jr, Bucana CD, Pollack VA (1980) Immunological stimulation in situ: the acute and chronic inflammatory responses in the induction of tumor immunity. Contemp Top Immunol 10:267–296.Google Scholar
  14. 14.
    Stephenson KR, Perry-Lalley D, Griffith KD, Shu S, Chang AE (1989) Development of antitumor reactivity in regional draining lymph nodes from tumor-immunized and tumor-bearing murine hosts. Surgery 105:523–528.PubMedGoogle Scholar
  15. 15.
    Chou T, Chang AE, Shu S (1988) Generation of therapeutic T lymphocytes from tumor-bearing mice by in vitro sensitization: culture requirements and characterization of immunologic specificity. J Immunol 140:2453–2461.PubMedGoogle Scholar
  16. 16.
    Shu S, Chou T, Rosenberg SA (1987) Generation from tumor-bearing mice of lymphoid cells with in vivo therapeutic efficacy. J Immunol 139:295–304.PubMedGoogle Scholar
  17. 17.
    Chang AE, Yoshizawa H, Sakai K, Cameron MJ, Sondak VK, Shu S (1993) Clinical observations on adoptive immunotherapy with vaccine-primed T lymphocytes secondarily sensitized to tumor in vitro. Cancer Res 53:1043–1050.PubMedGoogle Scholar
  18. 18.
    Yoshizawa H, Chang AE, Shu S (1992) Cellular interactions in effector cell generation and tumor regression mediated by anti-CD3/IL-2 activated tumor-draining lymph node cells. Cancer Research 52:1129–1136.PubMedGoogle Scholar
  19. 19.
    Kagamu H, Shu S (1998) Purification of L-selectinlow cells promotes the generation of highly potent CD4 antitumor or effector T lymphocytes. J Immunol 160:3444–3452.PubMedGoogle Scholar
  20. 20.
    Yoshizawa H, Chang AE, Shu S (1991) Specific adoptive immunotherapy mediated by tumor-draining lymph node cells sequentially activated with anti-CD3 and IL-2. J Immunol 147:729–737.PubMedGoogle Scholar
  21. 21.
    Plautz GE, Barnett GH, Miller DW, Cohen BH, Prayson RA, Krauss JC, Luciano M, Kangisser DB, Shu S (1998) Systemic T cell adoptive immunotherapy of malignant gliomas. J Neurosurg 89:42–51.PubMedCrossRefGoogle Scholar
  22. 22.
    Plautz GE, Miller DW, Barnett GH, Stevens GHJ, Maffett S, Kim J, Cohen PA, Shu S (2000) T cell immunotherapy of newly diagnosed gliomas. Clin Cancer Res 6:2209–2218.PubMedGoogle Scholar
  23. 23.
    Plautz GE, Bukowski RM, Novick AC, Klein EA, Kursh ED, Olencki TE, Yetman RJ, Pienkny A, Sandstrom K, Shu S (1999) T cell adoptive immunotherapy of metastatic renal cell carcinoma. Urology 54:617–624.PubMedCrossRefGoogle Scholar
  24. 24.
    To WC, Wood BG, Krauss JC, Strome M, Esclamado RM, Lavertu P, Dasko D, Kim JA, Plautz GE, Leff BE, Smith V, Sandstrom-Wakeling K, Shu S (2000) Systemic adoptive T cell immunotherapy in recurrent and metastatic carcinoma of head and neck: a phase I study. Arch Otolaryngol Head Neck Surg 126:1225–1231.PubMedGoogle Scholar
  25. 25.
    Steinman RM (1991) The dendritic cell system and its role in immunogenicity. Annu Rev Immunol 9:271–296.PubMedCrossRefGoogle Scholar
  26. 26.
    Hart DNJ (1997) Dendritic cells: unique leukocyte populations which control the primary immune response. Blood 90:3245–3287.PubMedGoogle Scholar
  27. 27.
    Steinman RM, Dhodapkar M (2001) Active immunization against cancer with dendritic cells: the near future. Int J Cancer 94:459–473.PubMedCrossRefGoogle Scholar
  28. 28.
    Engleman EG (2003) Dendritic cell-based cancer immunotherapy. Seminars in Oncol 30:23–27.CrossRefGoogle Scholar
  29. 29.
    Ridway D (2003) The first 1000 dendritic cell vaccines. Cancer Invest 21:873–886.CrossRefGoogle Scholar
  30. 30.
    Rosenberg SA, Yang JC, Restifo NP (2004) Cancer immunotherapy: moving beyond current vaccines. Nat Med 10:909–915.PubMedCrossRefGoogle Scholar
  31. 31.
    Gong J, Chen D, Kashiwaba M, Kufe D (1997) Induction of antitumor activity by immunization with fusion of dendritic and carcinoma cells. Nat Med 3:558–561.PubMedCrossRefGoogle Scholar
  32. 32.
    Gong J, Nikrui N, Chen D, Koido S, Wu Z, Tanaka Y, Cannistra S, Avigan D, Kufe D (2000) Fusions of human ovarian carcinoma cells with autologous or allogeneic dendritic cells induce antitumor immunity. J Immunol 165:1705–1711.PubMedGoogle Scholar
  33. 33.
    Gong J, Avigan D, Chen D, Wu Z, Koido S, Kashiwaba M, Kufe D (2000) Activation of antitumor cytotoxic T lymphocytes by fusions of human dendritic cells and breast carcinoma cells. PNAS 97:2715–2718.PubMedCrossRefGoogle Scholar
  34. 34.
    Kuriyama H, Shimizu K, Lee W, Kjaergaard J, Parkhurst MR, Cohen PA, Shu S (2004) Therapeutic vaccine generated by electrofusion of dendritic cells and tumour cells. Dev Biol (Basel) 116:157–166.Google Scholar
  35. 35.
    Hayashi T, Tanaka H, Tanaka J, Wang R, Averbook BJ, Cohen PA, Shu S (2002) Immunogenicity and therapeutic efficacy of dendritic-tumor hybrid cells generated by electrofusion. Clin Immunol 104:14–20.PubMedCrossRefGoogle Scholar
  36. 36.
    Parkhurst MR, DePan C, Riley JP, Rosenberg SA, Shu S (2003) Hybrids of dendritic cells and tumor cells generated by electrofusion simultaneously present immunodominant epitopes from multiple human tumor-associated antigens in the context of MHC class I and class II molecules. J Immunol 170:5317–5325.PubMedGoogle Scholar
  37. 37.
    Kjaergaard J, Shimizu K, Shu S (2003) Electrofusion of syngeneic dendritic cells and tumor generates potent therapeutic vaccine. Cell Immunol 225:65–74.PubMedCrossRefGoogle Scholar
  38. 38.
    Shimizu K, Kuriyama H, Kjaergaard J, Lee W, Tanaka H, Shu S (2004) Comparative analysis of antigen loading strategies of dendritic cells for tumor immunotherapy. J Immunother 27:265–272.PubMedCrossRefGoogle Scholar
  39. 39.
    Kjaergaard J, Wang L-X, Kuriyama H, Shu S, Plautz GE (2005) Active immunotherapy for advanced intracranial murine tumors by using dendritic cell-tumor cell fusion vaccines. J Neurosurg 103:156–164.PubMedCrossRefGoogle Scholar
  40. 40.
    Boon T, Coulie PG, Van den Eynde B (1997) Tumor antigens recognized by T cells. Immunol Today 18:267–268.PubMedCrossRefGoogle Scholar
  41. 41.
    Rosenberg SA (1999) A new era for cancer immunotherapy based on the genes that encode cancer antigens. Immunity 10:281–287.PubMedCrossRefGoogle Scholar
  42. 42.
    Cox AL, Skipper J, Chen Y, Henderson RA, Darrow TL, Shabanowitz J, Engelhard VH, Hunt DF, Slingluff Jr CL (1994) Identification of a peptide recognized by five melanoma-specific human cytotoxic T cells lines. Science 264:716–719.PubMedCrossRefGoogle Scholar
  43. 43.
    Hunt DF, Henderson RA, Shabanowitz J, Sakaguchi K, Michel H, Sevilir N, Cox AL, Appella E, Engelhard VH (1992) Characterization of peptides bound to the class I MHC molecule HLA-A2.1 by mass spectrometry. Science 255:1261–1263.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2007

Authors and Affiliations

  • Rongxiu Zheng
    • 1
  • Jorgen Kjaergaard
    • 2
  • Walter T. Lee
    • 1
  • Peter A. Cohen
    • 1
  • Suyu Shu
    • 1
  1. 1.Center for Surgery ResearchCleveland ClinicClevelandUSA
  2. 2.New England Inflammation and Tissue Protection InstituteNortheastern UniversityBostonUSA

Personalised recommendations